Zhao Jianqiang, Gu Liufang, Li Chengliang, Ma Weiguo, Ni Zengfeng
Department of Hematology and Oncology, First Affiliated Hospital of the Xi'an Medical University, 48# Fenghao West Road, Xi'an, 710077, Shaanxi, China,
Tumour Biol. 2014 Jul;35(7):6919-24. doi: 10.1007/s13277-014-1942-9. Epub 2014 Apr 16.
According to the previous studies, numerous biomarkers impact on the prognosis of acute myeloid leukemia (AML) and the prediction for AML had been improved tremendously in the past decades. However, accurate risk-stratification at diagnosis or prognosis remained difficult. In order to further investigate the prognosis evaluation biomarker, the transcription or expression of neuropilin-1 (NRP-1) in 87 AML patients and 32 non-malignant controls were examined. Real-time quantitative polymerase chain reaction (RT-PCR) and Western blot were used to detect the NRP-1 expression. Clinical data were collected and analyzed for the 87 AML patients. The results indicated that high NRP-1 expression discriminated the complete remission (CR) rate of AML patients (22.12 % vs. 68.04 % for AML, P < 0.01). De novo AML patients tended to express higher NRP-1 proteins than relapsed AML patients. The overall survival (OS) and relapse-free survival (RFS) rate of the high NRP-1 expression patients decreased significantly compared with the low NRP-1 expression patients (P < 0.001). NRP-1 was revealed to be an independent risk factor for OS in AML (P = 0.003). In conclusion, NRP-1 could predict the shorter OS and RFS rate, and also related with the CR response in AML. Therefore, NRP-1 may act as a more aggressive and promising predictor for the poor prognosis of AML.
根据先前的研究，众多生物标志物会影响急性髓系白血病（AML）的预后，并且在过去几十年中，对AML的预测有了极大的改善。然而，在诊断或预后时进行准确的风险分层仍然困难。为了进一步研究预后评估生物标志物，检测了87例AML患者和32例非恶性对照中神经纤毛蛋白-1（NRP-1）的转录或表达。采用实时定量聚合酶链反应（RT-PCR）和蛋白质印迹法检测NRP-1的表达。收集并分析了87例AML患者的临床资料。结果表明，高NRP-1表达可区分AML患者的完全缓解（CR）率（AML患者为22.12% vs. 68.04%，P < 0.01）。初发AML患者比复发AML患者倾向于表达更高的NRP-1蛋白。与低NRP-1表达患者相比，高NRP-1表达患者的总生存期（OS）和无复发生存期（RFS）率显著降低（P < 0.001）。NRP-1被证实是AML患者OS的独立危险因素（P = 0.003）。总之，NRP-1可预测较短的OS和RFS率，并且与AML的CR反应相关。因此，NRP-1可能是AML预后不良的一个更具侵袭性且有前景的预测指标。
